

Special Issue

Advances in Liver Oncology: Molecular Mechanisms and Therapeutic Innovations

Message from the Guest Editors

Liver cancer is among the highest hurdles in oncology. It includes hepatocellular carcinoma (HCC), cholangiocarcinoma, and metastasis in the liver. Even though enormous progress has been made in their diagnosis and treatment, these cancers remain great challenges since their biology is complex, they are often diagnosed at an advanced stage, and they do not respond to the standard therapies. The TME is a critical component in the evolution of liver cancers and metastases, dictating the fate of cancer cells by regulating survival, immune evasion, and therapeutic resistance. This special issue aspires to encompass the general outlook on recent updates of research in liver oncology, whether primary liver cancers or liver metastases. We would like to bring out the molecular mechanisms behind such diseases and present novel therapeutic strategies that may be devised to interfere with these processes. We welcome the submission of peer-reviewed original research, reviews, and communications dedicated to the basic science and translational research in liver oncology.

Guest Editors

Prof. Dr. Rui Caetano Oliveira

Department of Pathology, Centro Hospitalar e Universitário de Coimbra, 3000-075 Coimbra, Portugal

Dr. Rui Miguel Martins

Portuguese Oncology Institute of Coimbra, Coimbra, Portugal

Prof. Dr. José Guilherme Tralhão

1. Surgery Department, Unidade Local de Saude de Coimbra, Coimbra, Portugal
2. Faculdade de Medicina, Universidade de Coimbra, Portugal
3. ACIMAGO, Coimbra, Portugal
4. Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, Coimbra, Portugal

Deadline for manuscript submissions

31 October 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/218858

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).